Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
IR BioSciences Holdings Inc | 20.0 | 0.0x | --- |
VIA Pharmaceuticals Inc | 20.0 | 0.0x | --- |
Tengion Inc | 40.0 | 0.0x | --- |
Rebus Holdings Inc | 30.0 | 0.0x | --- |
Easton Pharmaceuticals Inc | 1.3K | 0.0x | --- |
Vaxxinity Inc | 25.4K | 0.0x | --- |
IR BioSciences Holdings, Inc. is a development-stage biotechnology company. The Company, through its wholly owned subsidiary, ImmuneRegen BioSciences, Inc. (ImmuneRegen), is engaged in the research and development of the drug candidate Homspera for use in therapies in pulmonology, immunology and hematology. The Company focuses on the research and development of therapies in the areas of pulmonary fibrosis, influenza infection and radiation-induced Neutropenia. Other areas of research include vaccine adjuvant activity evinced against certain forms of cancer and applications for wound healing and for regenerating or strengthening the human immune system, in part, through stimulating human adult stem cells.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $20.00 |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 17.1M |
IR BioSciences Holdings Inc does not pay a dividend. | |
Beta | --- |
EPS | $-0.36 |
Book Value | $-0.43 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.